Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
The administration of noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and ketamine has been shown to increase the extracellular concentration of glutamate and serotonin (5-HT) in the medial prefrontal cortex (mPFC). In the present work, we used in vivo microdialysis to examine the effects of the more potent noncompetitive NMDA receptor antagonist, MK-801, on the efflux of glutamate and 5-HT in the mPFC, and whether the MK-801-induced changes in the cortical efflux of both transmitters could be blocked by clozapine and haloperidol given systemically or intra-mPFC. The systemic, but not the local administration of MK-801, induced an increased efflux of 5-HT and glutamate, which suggests that the NMDA receptors responsible for these effects are located outside the mPFC, possibly in GABAergic neurons that tonically inhibit glutamatergic inputs to the mPFC. The MK-801-induced increases of extracellular glutamate and 5-HT were dependent on nerve impulse and the activation of mPFC AMPA/kainate receptors as they were blocked by tetrodotoxin and NBQX, respectively. Clozapine and haloperidol blocked the MK-801-induced increase in glutamate, whereas only clozapine was able to block the increased efflux of 5-HT. The local effects of clozapine and haloperidol paralleled those observed after systemic administration, which emphasizes the relevance of the mPFC as a site of action of these antipsychotic drugs in offsetting the neurochemical effects of MK-801. The ability of clozapine to block excessive cortical 5-HT efflux elicited by MK-801 might be related to the superior efficacy of this drug in treating negative/cognitive symptoms of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 4×
“Thus, all these findings suggest that NMDA receptor antagonists would attenuate the tonic activation of inhibitory (GABA) neurons (possibly, though not exclusively, in the hippocampus and/or the thalamus), which would result in a disinhibition of glutamatergic input to the mPFC (Olney and Farber, 1995; Moghaddam et al…”
BackgroundInfluentialGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Prefrontal cortex in the rat: Projections to subcortical autonomic, motor, and limbic centers
Gabbott, P. L. A., Warner, T. A., Jays, P. R. L., Salway, P., & Busby, S. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20738 · Cited by 1,227 · cited 1×
“Furthermore, only around 5% of projection neurons in the V layer of the mPFC project to the dorsal raphe nucleus, according to Gabbott et al. (2005).”
BackgroundThe spectrum of behaviors influenced by serotonin
Lucki, I. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00139-5 · Cited by 1,158
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Moghaddam, B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13387.x · Cited by 567
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · cited 2×
“Our results are consistent with other data showing that the increased locomotion and firing or EPSCs of putative pyramidal neurons of the mPFC following systemic administration of NMDA receptor antagonists (Suzuki et al, 2002; Jodo et al, 2003; Jackson et al, 2004) were not mimicked by intra-mPFC application of these…”
BackgroundResultCelada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · cited 1×
“Although this functional interplay between the mPFC and the dorsal raphe nucleus is well documented (Hajós et al, 1998; Celada et al, 2001; Martı́nRuiz et al, 2001; Amargós-Bosch et al, 2003; Lucas et al, 2005), we presently cannot rule out the possibility of a direct effect of MK-801 on…”
BackgroundSelf-citationNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 2×
“In fact, GABAergic interneurons in limbic cortex and hippocampus are extremely responsive to NMDA receptor antagonists in comparison with pyramidal neurons (Grunze et al, 1996; Li et al, 2002), and PCP is able to reduce cortical GABAergic function (Yonezawa et al, 1998).”
BackgroundLorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Jackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Brain microdialysis of GABA and glutamate: What does it signify?
Timmerman, W., & Westerink, B. H. C. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199711)27:3<242::aid-syn9>3.0.co;2-d · Cited by 388
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 385
Martı́n-Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 339
Self-citationClozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.
Bakshi, V. P., Swerdlow, N. R., & Geyer, M. A. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23831-9 · Cited by 329
Hajós, M., Richards, C. D., Székely, A. D., & Sharp, T. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00157-2 · Cited by 300
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei
Adell, A., Celada, P., Abellán, M. T., & Artigas, F. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00182-0 · Cited by 254
Self-citationHomayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., & Moghaddam, B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300417 · Cited by 252
Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors
Corbett, R., Camacho, F., Woods, A. T., Kerman, L. L., Fishkin, R. J., Brooks, K., & Dunn, R. W. (1995) · Psychopharmacology · doi:10.1007/bf02246146 · Cited by 248
Coyle, J., & Tsai, G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1709-2 · Cited by 230
Millan, M. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2199-1 · Cited by 221
Gleason, S. D., & Shannon, H. E. (1997) · Psychopharmacology · doi:10.1007/s002130050165 · Cited by 216
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine
Malhotra, A. K., Adler, C. M., Kennison, S. D., Elman, I., Pickar, D., & Breier, A. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00546-x · Cited by 200
Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex
Ellenbroek, B. A., Budde, S., & Cools, A. R. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00307-7 · Cited by 197
Berridge, C. W., Stratford, T. L., Foote, S. L., & Kelley, A. E. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199711)27:3<230::aid-syn8>3.0.co;2-e · Cited by 190
Carli, M., Baviera, M., Invernizzi, R. W., & Balducci, C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300893 · Cited by 187
Kuroda, M., Yokofujita, J., & Murakami, K. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00070-1 · Cited by 186
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
Lieberman, J. A. (1996) · PubMed · Cited by 167
Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study
Park, S., Püschel, J., Sauter, B. H., Rentsch, M., & Hell, D. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00370-9 · Cited by 161
Sharp, F. R., Tomitaka, M., Bernaudin, M., & Tomitaka, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01817-8 · Cited by 158
Takahata, R., & Moghaddam, B. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300127 · Cited by 150
Yonezawa, Y., Kuroki, T., Kawahara, T., Tashiro, N., & Uchimura, H. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01435-0 · Cited by 141
Krimer, L. S., & Goldman-Rakic, P. S. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-11-03788.2001 · Cited by 141 · cited 1×
“Neuropsychopharmacology Krimer and Goldman-Rakic, 2001).”
Millan, M. J., Brocco, M., Gobert, A., Joly, F., Bervoets, K., Rivet, J. ‐., Newman‐Tancredi, A., Audinot, V., & Maurel, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00858.x · Cited by 139
Cognitive function in schizophrenia
Weinberger, D. R., & Gallhofer, B. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199709004-00006 · Cited by 139
Lucas, G., Compan, V., Charnay, Y., Neve, R. L., Nestler, E. J., Bockaert, J., Barrot, M., & Debonnel, G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.023 · Cited by 137
Adams, B. W., & Moghaddam, B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01195-7 · Cited by 134
Li, Q., Clark, S., Lewis, D. V., & Wilson, W. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03070.2002 · Cited by 132
Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
Duncan, G. E., Leipzig, J. N., Mailman, R. B., & Lieberman, J. A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00926-3 · Cited by 131
Maurel-Remy, S., Bervoets, K., & Millan, M. J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00333-g · Cited by 130
Regulation of serotonin release by GABA and excitatory amino acids
Tao, R., & Auerbach, S. B. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400201 · Cited by 128
Hertel, P., Mathé, J. M., Nomikos, G. G., Iurlo, M., Mathé, A. A., & Svensson, T. H. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00138-6 · Cited by 127
Degenetais, E. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.7.782 · Cited by 127
Suzuki, Y., Jodo, E., Takeuchi, S., Niwa, S., & Kayama, Y. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00298-1 · Cited by 126
Daly, D. A., & Moghaddam, B. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90483-2 · Cited by 119
Schmidt, C. J., & Fadayel, G. M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13106-6 · Cited by 118
Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats
Martin, P., Carlsson, M. L., & Hjorth, S. (1998) · NeuroReport · doi:10.1097/00001756-199809140-00012 · Cited by 118
Jodo, E., Suzuki, Y., Katayama, T., Hoshino, K.-Y., Takeuchi, S., Niwa, S.-I., & Kayama, Y. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhh168 · Cited by 116
Mathé, J. M., Nomikos, G. G., Blakeman, K. H., & Svensson, T. H. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00163-4 · Cited by 108
Amargós-Bosch, M., López-Gil, X., Artigas, F., & Adell, A. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005900 · Cited by 104
Self-citationBerridge, C. W., Mitton, E., Clark, W., & Roth, R. H. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990601)32:3<187::aid-syn5>3.0.co;2-9 · Cited by 101
Fujiyama, F., Kuramoto, E., Okamoto, K., Hioki, H., Furuta, T., Zhou, L., Nomura, S., & Kaneko, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03807.x · Cited by 99
Jentsch, J. D., Tran, A., Taylor, J. R., & Roth, R. H. (1998) · Psychopharmacology · doi:10.1007/s002130050649 · Cited by 97
Babot, Z., Cristòfol, R. M., & Sunol, C. E. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03848.x · Cited by 86
Self-citationHeidbreder, C. A., Foxton, R. H., Cilia, J., Hughes, Z. A., Shah, A. J., Atkins, A. R., Hunter, J. A., Hagan, J. J., & Jones, D. N. C. (2001) · Psychopharmacology · doi:10.1007/s002130100760 · Cited by 84
Brain region effects of clozapine on amino acid and monoamine transmission.
Yamamoto, B. K., Pehek, E. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 83
Bourdelais, A. J., & Deutch, A. Y. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.1.69 · Cited by 82
Gigg, J., Tan, A. M., & Finch, D. M. (1994) · Hippocampus · doi:10.1002/hipo.450040209 · Cited by 77
Tomitaka, S., Tomitaka, M., Tolliver, B. K., & Sharp, F. R. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00018.x · Cited by 69
D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons
Wang, Y., & Goldman-Rakic, P. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400954101 · Cited by 67
A microdialysis study of the in vivo release of 5‐HT in the median raphe nucleus of the rat
Adell, A., & Artigas, F. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702206 · Cited by 65
Self-citationAmargós‐Bosch, M., Adell, A., Bortolozzi, A., & Artigas, F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02044.x · Cited by 61
Self-citationTimmerman, W., Cisci, G., Nap, A., Vries, J. B. D., & Westerink, B. H. C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01538-3 · Cited by 60
Cartmell, J., Perry, K. W., Salhoff, C. R., Monn, J. A., & Schoepp, D. D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00034-x · Cited by 51
Effects of dizocilpine (MK 801) on noradrenaline, serotonin and dopamine release and uptake
Callado, L. F., Hopwood, S. E., Hancock, P. J., & Stamford, J. A. (2000) · Neuroreport · doi:10.1097/00001756-200001170-00034 · Cited by 44
Homayoun, H., & Moghaddam, B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.016 · Cited by 43
PATEL, D. R., Young, A. M. J., & Croucher, M. J. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00463-2 · Cited by 42
Väisänen, J., Lindén, A. M., Lakso, M., Wong, G., Heinemann, U., & Castrén, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00006-8 · Cited by 31
Jodo, E., Suzuki, Y., Takeuchi, S., Niwa, S., & Kayama, Y. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03967-7 · Cited by 28
Iravani, M. M., Muscat, R., & Kruk, Z. L. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990601)32:3<212::aid-syn7>3.0.co;2-m · Cited by 27
Maione, S., Rossi, F., Biggs, C. S., Fowler, L. J., & Whitton, P. S. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00101-5 · Cited by 21
Hondo, H., Nakahara, T., Nakamura, K., Hirano, M., Uchimura, H., & Tashiro, N. (1995) · Brain Research · doi:10.1016/0006-8993(94)01319-d · Cited by 20
Langman, N., SMITH, C., & WHITEHEAD, K. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.10.003 · Cited by 8
Acute D2/D3 Dopaminergic Agonism but Chronic D2/D3 Antagonism Prevents NMDA Antagonist Neurotoxicity
Farber, N. B., Nemmers, B., & Noguchi, K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.019 · Cited by 3
(1996) · doi:10.1002/(sici)1096-9861(19960520)369:1<1::aid-cne1>3.0.co;2-7
Cited by
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
“MK-801 into rat prefrontal cortex lacked any effect on serotonin and glutamate levels (López-Gil et al., 2007).”
BackgroundYan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK801-induced glutamate release in PFC of rats [169].”
BackgroundLinge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 279
Self-citation
Metadata
- Authors
- López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Adell, Albert
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-14
- Volume
- 32
- Issue
- 10
- Pages
- 2087-2097
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2084299214
- Cited by
- 183
- References
- 89
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 16 · 2013: 13 · 2012: 7
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Generalitat de Catalunya (SGR-2005)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- clozapine, haloperidol, MK-801, NMDA receptor antagonists, medial prefrontal cortex, glutamate efflux, serotonin efflux, non-NMDA receptors, antipsychotic drugs, negative symptoms of schizophrenia, cognitive symptoms, tetrodotoxin, NBQX, local drug administration
- MeSH terms
- Animals, Clozapine, gamma-Aminobutyric Acid, Haloperidol, Male, Synaptic Transmission, Schizophrenia, Serotonin, Antipsychotic Agents, Dizocilpine Maleate, Rats, Wistar, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Excitatory Amino Acid Antagonists, Glutamic Acid, Extracellular Fluid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.